Cargando…

Gene transfer using bovine adeno-associated virus in the guinea pig cochlea

Gene transfer into cells of the cochlea is useful for both research and therapy. Bovine adeno-associated virus (BAAV) is a novel viral vector with potential for long term gene expression with little or no side effects. In this study we assessed transgene expression using BAAV with ß-actin-GFP as a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibata, Seiji B., Di Pasquale, Giovanni, Cortez, Sarah R., Chiorini, John A., Raphael, Yehoash
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726904/
https://www.ncbi.nlm.nih.gov/pubmed/19458651
http://dx.doi.org/10.1038/gt.2009.57
Descripción
Sumario:Gene transfer into cells of the cochlea is useful for both research and therapy. Bovine adeno-associated virus (BAAV) is a novel viral vector with potential for long term gene expression with little or no side effects. In this study we assessed transgene expression using BAAV with ß-actin-GFP as a reporter gene, in cochleae of normal and deafened guinea pigs. We used two different routes to inoculate the cochlea: scala media (SM) or scala tympani (ST). Auditory brainstem response assessments were done prior to inoculation, 7 days after inoculation and immediately prior to sacrifice, to assess the functional consequences of the treatment. We observed threshold shifts due to the surgical invasion, but no apparent pathology associated with the virus. Fourteen days after the injection, animals were sacrificed and cochleae assessed histologically. Epi-fluorescence showed that BAAV transduced the supporting cells of both normal and deafened animals through SM and ST inoculations. Transgene expression in cells of the membranous labyrinth following ST inoculation is an important outcome because of the greater feasibility of this route for future clinical application. BAAV facilitates efficient transduction of the membranous labyrinth epithelium with minimum pathogenicity and may become clinically applicable for inner ear gene therapy.